{
    "clinical_study": {
        "@rank": "141249", 
        "acronym": "ZTOG-1202", 
        "arm_group": {
            "arm_group_label": "Neoadjuvant Treatment", 
            "arm_group_type": "Experimental", 
            "description": "Neoadjuvant Chemoradiotherapy"
        }, 
        "brief_summary": {
            "textblock": "The investigators hypothesized that the Neoadjuvant Chemoradiotherapy was a beneficial\n      treatment for Patients with Stage IIIA-N2 Non-Small Cell Lung Cancer, so we try to evaluate\n      the security of treatment, the QoL of patients and the influence to the PFS and OS."
        }, 
        "brief_title": "Phase II Trial of Regimen for Stage III (N2) NSCLC Using Induction Treatment Followed by Resection", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-small Cell Lung Cancer Stage IIIA", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Scheme:\n\n      Patients will receive different chemotherapy regimens depending on the pathological type.\n\n      Squamous cell carcinoma:Docetaxel/Cisplatin and concurrent radiation (46Gy/23f) followed by\n      surgery, consolidate Docetaxel/Cisplatin 2 cycles.\n\n      Non-squamous cell carcinoma:Pemetrexed/Cisplatin and concurrent radiation (46Gy/23f)\n      followed by surgery, consolidate Pemetrexed/Cisplatin 2 cycles."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18\u2264Age\u226465;\n\n          -  ECOG performance status of 0 or 1;\n\n          -  Pathological diagnosis with Stage IIIA-N2 NSCLC which is clinically resectable and\n             the N2 is diagnosed by either mediastinoscopy,EBUS,PET/CT;\n\n          -  WBC\u22654.0\u00d7109/l, ANC\u22651.5\u00d7109/l, PLT\u2265100.0\u00d7109/l, Hb\u226590g/l;hepatorenal function is\n             normal;\n\n          -  Without a history of other malignancies before enrollment, except for non-melanoma\n             skin cancer, in situ cervical cancer;\n\n          -  The patient can understand the research and sign the informed consent.\n\n        Exclusion Criteria:\n\n          -  Female in pregnancy or lactating;Female of childbearing age without contraception;\n\n          -  With acute infection or other serious underlying disease;\n\n          -  With a significant history of neurological of psychiatric disease\uff0cincluding the\n             dementia which may affect the ability to understand and sign the informed consent;\n\n          -  Have received other treatment within the last 30 days before enrollment;\n\n          -  With uncontrollable diabetes(blood glucose is unstable after treatment or\n             FBG\u22658mol/L)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01926483", 
            "org_study_id": "ZTOG-1202"
        }, 
        "intervention": {
            "arm_group_label": "Neoadjuvant Treatment", 
            "description": "Surgery followed by cisplatin-based regimen and concurrent radiation (46Gy/23f), consolidate the original regimen 2 cycles.", 
            "intervention_name": "Neoadjuvant Chemoradiotherapy", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Stage IIIA-N2 NSCLC", 
        "lastchanged_date": "August 16, 2013", 
        "location": {
            "contact": {
                "email": "xuyaping1207@gmail.com", 
                "last_name": "Xu Yaping", 
                "phone": "+0086-571-88122082"
            }, 
            "facility": {
                "address": {
                    "city": "Hangzhou", 
                    "country": "China", 
                    "state": "Zhejiang", 
                    "zip": "310022"
                }, 
                "name": "Zhejiang Cancer Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Prospective, Phase II Trial of a Trimodality Regimen for Stage III (N2) Non-small-cell Lung Cancer Using Concurrent Chemoradiotherapy as Induction Treatment Followed by Subsequent Resection", 
        "overall_contact": {
            "email": "maowmzj1218@163.com", 
            "last_name": "Weiming Mao, MD", 
            "phone": "+86-571-88122032"
        }, 
        "overall_contact_backup": {
            "email": "xuyaping1207@gmail.com", 
            "last_name": "Yaping Xu, MD", 
            "phone": "+86-571-88128168"
        }, 
        "overall_official": {
            "affiliation": "Zhejiang Cancer Hospital", 
            "last_name": "Weimin Mao, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "PFS", 
            "safety_issue": "Yes", 
            "time_frame": "up to 3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01926483"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "observe and record the toxicity profile(including but not limit to mucositis,liver and kidney function,et al.)according NCI-CTCAE(3rd edition) during the neoadjuvant chemoradiation and follow-up.", 
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "participants will be followed for the duration of hospital stay,an expected average of 100 days and every 3 months thereafter for 5 years"
            }, 
            {
                "measure": "QOL", 
                "safety_issue": "Yes", 
                "time_frame": "up to 3 years"
            }, 
            {
                "measure": "OS", 
                "safety_issue": "Yes", 
                "time_frame": "up to 3 years"
            }
        ], 
        "source": "Zhejiang Cancer Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Zhejiang Cancer Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2012"
    }
}